The stocks cheap at .167 and looks to move north on news. The company announced they received FDA breakthrough designation for their panel
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
Molecular Diagnostic Test for Early Detection of Lyme Disease
LEXINGTON, Mass., July 11, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Company’s T2Lyme™ Panel.